CHIH-HUNG WANGLi, Cheng-HanCheng-HanLiHsieh, RonanRonanHsiehFan, Cheng-YiCheng-YiFanHsu, Tze-ChunTze-ChunHsuChang, Wei-CheWei-CheChangHsu, Wan-TingWan-TingHsuLin, Yu-YaYu-YaLinCHIEN-CHANG LEE2019-09-232019-09-232019-031474-0338https://scholars.lib.ntu.edu.tw/handle/123456789/424818We aimed to summarize the current evidence regarding the risk of pneumonia associated with proton pump inhibitors (PPI) treatment.enMeta-analysis; pneumonia; proton pump inhibitors; protopathic bias[SDGs]SDG3nonsteroid antiinflammatory agent; proton pump inhibitor; nonsteroid antiinflammatory agent; proton pump inhibitor; Article; disease association; drug effect; Embase; evidence based practice; genetic heterogeneity; high risk patient; human; infection risk; Medline; meta analysis; observational study; pneumonia; publication bias; quality control; randomized controlled trial (topic); risk assessment; risk evaluation and mitigation strategy; sensitivity analysis; systematic review; methodology; pneumonia; publishing; statistical analysis; statistical model; Anti-Inflammatory Agents, Non-Steroidal; Data Interpretation, Statistical; Humans; Models, Statistical; Pneumonia; Proton Pump Inhibitors; Publication Bias; Randomized Controlled Trials as Topic; Research Designjournal articlehttps://api.elsevier.com/content/abstract/scopus_id/8506235487210.1080/14740338.2019.1577820307043062-s2.0-85062354872WOS:000463105200002https://api.elsevier.com/content/abstract/scopus_id/85062354872